Skip to content
value.today
Arcadia Biosciences, Inc. logo

Arcadia Biosciences, Inc.

RKDA
$1 Mmarket cap on Oct 30, 2026-65.7% since Jan 2024
Compare
World rank
#27,997
Revenue
$5 M
For year ending December-2025
Net income
$-2 M
-48.1% margin
SEC filing
Employees
—

Arcadia Biosciences, Inc. in brief

Arcadia Biosciences, Inc. is a listed company in the Agriculture Related industry, based in Dallas, Texas, USA. It was founded in 2002. Its market value was $1 M on 30 October 2026, which makes it the 27,997th largest listed company in the world and the 4,516th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $2 M. By market, the largest shares of its 2025 sales came from USA (100%). Its shares trade under the symbol RKDA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Arcadia Biosciences, Inc.

Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.

It has developed a reduced-gluten and enhanced starch variety of wheat under the name GoodWheat. Arcadia also has a joint venture with Bioceres called Verdeca, which has developed and is commercializing HB4 technology in soybeans that gained FDA approval in 2017. HB4 soybeans have increased yield up to 30% while being more resistant to abiotic stress such as drought.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Arcadia Biosciences, Inc. timeline

4 events, 2002–2020
  1. 2002
  2. 🏁
    · approximate
    Founded
  3. 2009
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2015
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 15 May 2015; shares registered for exchange trading on 8 May 2015.
  7. 2020
  8. 💰
    Record revenue of $8 million
    FY2020, the highest of the 8 years on record.

Events of Arcadia Biosciences, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$13 M$26 M$39 M$52 M2020202120222023202420252026

World rank over time

▼ down 5,893 places since 2020
2020-01-01: #22110#22,11020202021-01-01: #21856#21,85620212022-01-07: #28796#28,79620222022-12-25: #32236#32,23620222023-07-30: #33279#33,27920232024-01-05: #32915#32,91520242026-03-08: #13385#13,38520262026-08-01: #24081#24,08120262026-10-14: #27906#27,90620262026-10-30: #28003#28,0032026

Rank in USA: #4,148 (Jan 2020) · #4,230 (Jan 2021) · #5,281 (Jan 2022) · #5,674 (Dec 2022) · #5,654 (Jul 2023) · #4,685 (Jan 2024) · #2,469 (Mar 2026) · #4,172 (Aug 2026) · #4,445 (Oct 2026) · #4,519 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.2×
Price / book
0.2×
Free cash flow yield
-460.2%
Net margin (TTM)
-202.2%
Operating margin
-51.4%
Return on equity
-247.1%
Liabilities / assets
36.8%
Net debt
$-29M
Revenue growth
-3.6%
R&D / revenue
0.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-13M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-29M$1MFY19Fiscal year ending Dec 2020: revenue $8M, net income $-5M$8MFY20Fiscal year ending Dec 2021: revenue $7M, net income $-15M$7MFY21Fiscal year ending Dec 2022: revenue $7M, net income $-15M$7MFY22Fiscal year ending Dec 2023: revenue $4M, net income $-14M$4MFY23Fiscal year ending Dec 2024: revenue $5M, net income $-7M$5MFY24Fiscal year ending Dec 2025: revenue $5M, net income $-2M$5MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$5M-3.6%$-3M$-2M-48.1%
Dec 2024$5M+13.3%$-4M$-7M-139.7%
Dec 2023$4M-40.0%$-6M$-14M-314.2%
Dec 2022$7M+9.4%$-14M$-15M-207.3%
Dec 2021$7M-15.6%$-36M$-15M-216.2%
Dec 2020$8M+586.3%$-13M$-5M-58.0%
Dec 2019$1M-19.9%$-19M$-29M-2461.5%
Dec 2018$1M—$-17M$-13M-923.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$0M$-5M$-1.71—
Dec 2024$-10M$0M$-10M$-5.17—
Dec 2023$-15M$0M$-15M$-11.29—
Dec 2022$-14M$0M$-14M$-25.65—
Dec 2021$-26M$1M$-27M$-27.56—
Dec 2020$-30M$2M$-33M$-0.47—
Dec 2019$-17M$1M$-19M$-4.53—
Dec 2018$-14M$0M$-14M$-3.58—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$5M
Net income, trailing 12 months
$-10M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-4M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $3M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-4M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $1M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-1M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-4M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-6M$1MJun ’26Three months to Sep 2026: revenue $2M, net income $2M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (+24.6% on a year earlier), net income $2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Arcadia Biosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$5 M
Operating income
$-3 M
Net income
$-2 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$2 M
Total equity
$4 M

As of December-2025

Top 17 institutional investors in Arcadia Biosciences, Inc.#

As of Sep 30, 2026
17 institutions held 618,797 shares (about 10.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 10.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 17 largest institutional investors in Arcadia Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC476,422New7.86%$0 MNov 16, 2026
2Two Sigma Securities, LLC30,904New0.51%$0 MNov 16, 2026
3HRT Financial LP26,092-62,294 (-70.48%)0.43%$0 MNov 13, 2026
4Jump Financial, LLC24,301New0.40%$0 MNov 13, 2026
5Citadel Advisors LLC22,887-851 (-3.58%)0.38%$0 MNov 16, 2026
6Geode Capital Management, LLC16,1350 (0.00%)0.27%$0 MNov 6, 2026
7State Street Corp12,1460 (0.00%)0.20%$0 MNov 12, 2026
8Vanguard Capital Management LLC9,6440 (0.00%)0.16%$0 MNov 13, 2026
9SBI Securities Co., Ltd.1200 (0.00%)0.00%$0 MOct 22, 2026
10TD Waterhouse Canada Inc.700 (0.00%)0.00%$0 MOct 16, 2026
11UBS Group AG44+9 (+25.71%)0.00%$0 MNov 10, 2026
12Group One Trading LLC180 (0.00%)0.00%$0 MNov 10, 2026
13Pinnacle Financial Group, Inc.8—0.00%$0 MNov 16, 2026
14Morgan Stanley20 (0.00%)0.00%$0 MNov 13, 2026
15Southern Michigan Bank & Trust20 (0.00%)0.00%$0 MOct 19, 2026
16Barclays PLC1New0.00%$0 MNov 6, 2026
17Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding Arcadia Biosciences, Inc.#

4 funds hold shares worth $0 M (about 0.7% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Arcadia Biosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC27,879$0 M0.46%<0.01%+304%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.9,644$0 M0.16%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,716$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC1,626$0 M0.03%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Arcadia Biosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
22
since
$2 K$0Feb 2024: bought $1 K (1 trades), sold $0 (0 trades)Feb 24Aug 2024: bought $1 K (2 trades), sold $0 (0 trades)AugFeb 2025: bought $2 K (2 trades), sold $0 (0 trades)Feb
Bought (open market)Sold (open market)Hover a month for the totals
Arcadia Biosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Thomas J. SchaeferChief Executive OfficerBuy+700$2.490$2 K2,819Form 4
filed Mark KawakamiChief Financial OfficerBuy+700$2.490—2,681Form 4
filed Thomas J. SchaeferChief Executive OfficerBuy+700$2.060$1 K2,119Form 4
filed Mark KawakamiChief Financial OfficerBuy+700$2.060—1,981Form 4
filed Thomas J. SchaeferChief Financial OfficerBuy+700$2.060$1 K1,419Form 4
filed Thomas J. SchaeferChief Financial OfficerBuy+649$3.670$2 K719Form 4
filed Stanley Jacot Jr.Chief Executive OfficerBuy+5,000$4.310$22 K5,000Form 4
filed Thomas J. SchaeferChief Financial OfficerBuy+700$0.230$1612,800Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Arcadia Biosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
115,580
8.4% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split in the period to

Trading halts

  • 2025-10-08 18:14 UTC, code LUDP, resumed 18:24 UTC
  • 2025-10-08 18:09 UTC, code LUDP, resumed 18:14 UTC
  • 2024-11-15 14:58 UTC, code LUDP, resumed 15:03 UTC
  • 2024-11-15 14:53 UTC, code LUDP, resumed 14:58 UTC

Fails to deliver

  • : 3,565 shares at $0.17
  • : 18,415 shares at $0.20
  • : 107,594 shares at $0.20
  • : 840,555 shares at $0.21
  • : 35,719 shares at $0.28

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Arcadia Biosciences, Inc. scorecard#

Passes 6 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.2×Price to book 0.2× against Agriculture Related's median of 1.7×.
    • ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Agriculture Related's median of 1.2×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-3.6%Revenue down 3.6% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-13.2%-13.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-13.2%-13.2% a year against Agriculture Related's median of -10.4% (14 companies).
    • ✗Earnings per share grew in the newest year-1.71 vs -5.17Diluted EPS -1.71 in fiscal 2025 against -5.17 the year before (report's currency).
    • ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2025 against -$5 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-51.4%-51.4% against Agriculture Related's median of 5.2% (14 companies).
    • ✗Return on equity above 15%-45.2%-45.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-51.4%-51.4% in fiscal 2025 against -188.8% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.1×Current ratio 3.09 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-59.58Z-score -59.58 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.4%Diluted shares up 0.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Agriculture Related, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Arcadia Biosciences, Inc.'s statements, beside the median of Agriculture Related.

Arcadia Biosciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-51.4%5.2%
Net margin-48.2%3.5%
Return on equity-45.2%2.3%
Revenue growth, 3 years a year-13.2%-10.4%
Revenue growth-3.6%-3.8%
Free cash flow margin-97.5%8.0%

2of 8on the Piotroski tests of financial strength

  • Revenue fell 3.6% against the year before.
  • Net loss of $2 million, the 12th loss-making year in a row.
  • Free cash flow was negative: -$5 million.

Arcadia Biosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Arcadia Biosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue4.95.04.5r7.4r6.88.01.21.54.03.2
Cost of revenue3.13.02.2r6.1r8.75.2——0.30.9
Research and development0.00.10.1r1.53.98.07.16.17.48.7
Selling, general and administrative7.09.68.2r15r231614121112
Operating expenses—————2121181822
Total costs and expenses7.48.711r21r4221————
Operating income−2.5−3.6−6.1r−14r−36−13−19−17−14−19
Interest expense and finance costs————0.00.00.0—0.71.3
Net interest income0.20.80.70.3−0.0—————
Other non-operating income (expense)2.30.00.00.0r100.70.50.40.30.3
Income before tax−2.3−4.3−5.3r−11r−16−6.2−29−13−16−20
Income tax0.00.00.00.00.0−0.10.00.00.00.0
Income from discontinued operations——−0.8−4.8——————
Net income including minority interests−2.3−7.0−14−16−16−6.0−29−13——
Minority interests' share of net income—0−0.0−0.2−1.5−1.4−0.1———
Net income attributable to shareholders−2.3−7.0−14−15−15−4.7−29−13−16−20
Earnings per share, basic-1.71-5.17-11.29-25.65-27.56r-0.47-4.53-3.58-7.28-8.85r
Earnings per share, diluted-1.71-5.17-11.29-25.65-27.56r-0.47-4.53-3.58-7.28-8.85r
Shares, weighted average (basic)1.41.41.20.60.5—————
Shares, weighted average (diluted)1.41.41.20.60.5r10.06.43.82.22.2r
Balance sheet
Cash and cash equivalents0.34.26.52129148.4129.12.0
Short-term investments4.305.10—12179.83.949
Receivables————1.41.40.60.21.20.3
Inventory1.20.90.8r2.3r4.43.81.80.20.20.3
Other current assets0.20.90.80.8r0.90.80.70.70.60.9
Current assets6.49.21525353228231552
Property, plant and equipment0.00.00.1r0.7r2.33.51.80.40.30.5
Right-of-use (leased) assets00.10.81.83.15.82.0———
Goodwill—————0.4————
Other intangible assets0.00.00.00.00.50.4————
Long-term investments—————————2.5
Total assets6.5142029444733241757
Accounts payable1.50.7r0.5r0.9r1.4r0.7r0.5r0.3r0.4r0.2r
Debt due within a year————01.10.0——0
Current liabilities2.12.63.64.25.06.35.73.13.53.1
Long-term debt————02.10.1——25
Lease liabilities (non-current)—00.21.02.25.41.5———
Total liabilities2.47.37.08.0131924118.634
Retained earnings−281−279−272−258−226−212−207−178−167−152
Shareholders' equity—6.2132131287.7138.022
Minority interests—0−0.1−0.10.10.80.6———
Total equity4.16.2132131298.3r138.0—
Total liabilities and equity6.5142029444733241757
Shares outstanding1.41.41.30.60.6r138.64.82.12.2r
Cash-flow statement
Depreciation and amortization———————0.20.30.3
Share-based compensation0.20.50.71.11.52.02.31.61.51.1
Cash from operating activities−4.7−9.6−15−14−26−30−17−14−14−17
Capital expenditure0−0.0−0.0−0.1−1.0−2.3−1.5−0.3−0.1−0.2
Acquisitions, net of cash acquired———0−4.3−0.5————
Cash from investing activities0.87.3−4.31.41717−8.4−6.047−5.3
Cash from financing activities0.00.05.54.522212222−260.4
Change in cash−4.0−2.3−14−8.0137.6−3.62.97.1−22
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Arcadia Biosciences, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$5 M100%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Arcadia Biosciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$469 K
Other top executives, average
$218 K
the CEO earned 2.1× this
$100 invested is now
$36
Arcadia Biosciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$469 K$380 K$218 K$36
2024Chief executive$518 K$532 K$263 K—
2023Chief executive$525 K$488 K$363 K$8

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Arcadia Biosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 2 · Auditor changed 1 · Change in control 1 · Directors and officers 6 · Material agreement 5 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Shareholder vote 2 · Results announced 9

Arcadia Biosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Directors and officers8-K
Material agreementUnregistered share saleShareholder rights changed8-K
Agreement ended8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Change in controlDirectors and officersMaterial agreement8-K
Results announced8-K
Directors and officers8-K/A

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 acquisitions · 3 private funding rounds before listing

Businesses it acquired

Acquisitions by Arcadia Biosciences, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Anawah, IncJun 2005Jun 2005——Annual report

Private share sales · funding history

Private share sales of Arcadia Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$4 MPrivate placement after listing$2 to $10 million5equity, optionsSEC
Jan 2026$2 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Jan 2021$25 MPrivate placement after listing$10 to $50 million26equity, optionsSEC
Mar 2018$10 MPrivate placement after listing$10 to $50 million2equity, optionsSEC
Mar 2014$19 MNo. 3$10 to $50 million8equity, optionsSEC
Oct 2009$2 MNo. 2$2 to $10 million6equitySEC
Jul 2008$15 MNo. 1$10 to $50 million9equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Arcadia Biosciences, Inc.#

2 labor condition applications certified in fiscal 2021 for 2 positions, at a median wage of $94 K a year.

Certified, FY2021
2
#1,646 among companies on value.today
Worker positions
2
Median wage offered
$94 K
a year, full-time
Applications filed
2
Arcadia Biosciences, Inc.: most frequent H-1B job titles in fiscal 2021
Job titlePositionsMedian wage offered
MANAGER DEMAND AND SUPPLY PLANNINGTransportation, Storage, and Distribution Managers2$94 K

Where: Davis, CA 2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ARCADIA BIOSCIENCES, INC.

How Arcadia Biosciences, Inc. compares in Agriculture Related

  • Market cap$1 M · higher than 1% of 172
  • Revenue$5 M · higher than 2% of 51
  • Net margin-202.2% · higher than 0% of 49
  • Revenue growth-3.6% · higher than 55% of 21
  • Price / sales0.2× · lower than 94% of 49
  • Price / book0.3× · lower than 93% of 42

Peer comparison · Agriculture Related

CompanyMarket capP/ENet marginRev. growth
Arcadia Biosciences, Inc.🇺🇸$1 M—-202.2%-3.6%
Corteva, Inc.🇺🇸$51.2 B67.4×4.3%+2.9%
Nutrien Ltd.🇨🇦$33.0 B14.6×8.4%+3.5%
Qinghai Salt Lake Industry Co., Ltd🇨🇳$22.2 B18.1×54.7%—
Zangge Holding Company🇨🇳$18.1 B32.4×——
CF Industries Holdings, Inc.🇺🇸$17.7 B6.9×32.2%+19.3%
Saudi Arabian Fertilizers Company🇸🇦$15.5 B13.5×33.0%-17.3%
Yara International ASA🇳🇴$11.4 B8.3×8.8%—
Shandong Hualu-Hengsheng Chemical Co., Ltd.🇨🇳$8.4 B17.5×10.7%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Arcadia Biosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Arcadia Biosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Arcadia Biosciences, Inc.? Suggest a correction